STAT+: New analysis of Amarin’s Vascepa resurrects big questions about effectiveness
A new analysis of Vascepa, a medicine derived from fish oil and used to prevent heart attacks in a select group of patients, raises big questions about the evidence that the medicine is effective. Several experts say the questions require a new clinical trial to be conducted, and some even say the Food and Drug Administration should reconsider the product’s approval.
In a twist, the new data come from an analysis funded by Amarin itself.
Continue to STAT+ to read the full story…
